Teresa Graham, Chief Executive of Roche’s pharma division, said in an interview with The Wall Street Journal’s Helena Smolak that the company is narrowing the targets in its pharmaceutical research and development activities to 11 disease areas and continuing to invest in a targeted way as it pushes into the “increasingly crowded” obesity field and expands in therapeutic areas such as ophthalmology. “We did a very thorough scrub of our portfolio and we’ve cut about 25% of our pipeline,” Graham is quoted as having said. Roche, which is seeking closer alignment between its pharmaceutical and diagnostics divisions, plans to provide more details about its group and pharma strategy at an investor event on September 30, The Journal noted.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RHHBY:
- Roche launches the first test to use its breakthrough TAGS technology for high throughput, simultaneous detection of 12 respiratory viruses
- WHO endorses dual-stain cytology (CINtec PLUS) testing in its cervical cancer prevention guidelines, advancing patient care and underlining Roche’s role in pioneering cervical cancer solutions
- Genentech announces CENTERSTONE study meets primary endpoint
- Positive phase III results show Xofluza significantly reduces the transmission of influenza viruses
- FDA approves OCREVUS ZUNOVO™ as the first and only twice-a-year 10-minute subcutaneous injection for people with relapsing and progressive multiple sclerosis
Questions or Comments about the article? Write to editor@tipranks.com